脑转移癌全脑同期推量IMRT疗效初步分析

目的 初步研究全脑同期推量调强放疗(SIB-IMRT)对脑转移癌患者疗效。方法 2016-2017 年收治的52例脑转移癌患者作为观察对象。随机均分为两组,观察组为SIB-IMRT,对照组为常规全脑放疗。初步对比两组疗效。结果 两组病患全部顺利完成治疗。观察组客观缓解率明显高于对照组(77%∶27%,P=0.00),中位生存期观察组也长于对照组(384 d∶211 d,P=0.00)。急性不良反应主要为1-2 级反应。结论 SIB-IMRT治疗脑转移癌疗效显著,不良反应可耐受,值得进一步深入研究。

Preliminary analysis of clinical efficacy of whole brain simultaneous integrated boost intensity-modulated radiotherapy in patients with brain metastases

Objective To preliminary investigate the clinical efficacy of whole brain simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT) in patients diagnosed with brain metastases (BM). Methods Fifty-two cases of BM admitted to our hospital from January 2016 to December 2017 were equally recruited and randomly divided into the observation and control groups. Patients in the observation group were treated with SIB-IMRT,and those in the control group received conventional whole brain radiotherapy (WBRT).The clinical efficacy and prognosis were statistically compared between two groups. Results The ORR in the observation group was 77%,significantly higher than 27% in the control group (P=0.00).The median survival in the observation group was 384 d,significantly longer compared with 211 d in the control group (P=0.00).All patients in both groups successfully completed corresponding treatment. Acute adverse reactions were mainly 1-2 grade reactions. Conclusions SIB-IMRT is an efficacious and safe treatment of BM,which yields tolerable adverse events and deserves application in clinical practice.